0001144204-15-066696.txt : 20151118
0001144204-15-066696.hdr.sgml : 20151118
20151118160843
ACCESSION NUMBER: 0001144204-15-066696
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151116
FILED AS OF DATE: 20151118
DATE AS OF CHANGE: 20151118
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001293310
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770557236
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 442 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.243.3100
MAIL ADDRESS:
STREET 1: 442 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shkreli Martin
CENTRAL INDEX KEY: 0001525354
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35798
FILM NUMBER: 151240846
MAIL ADDRESS:
STREET 1: 330 MADISON AVENUE, 6TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
4
1
v425127_4.xml
OWNERSHIP DOCUMENT
X0306
4
2015-11-16
0
0001293310
KALOBIOS PHARMACEUTICALS INC
KBIO
0001525354
Shkreli Martin
C/O TURING PHARMACEUTICALS LLC
1177 AVENUE OF THE AMERICAS, 39TH FLOOR
NEW YORK
NY
10036
0
0
1
0
Common Stock
2015-11-16
4
P
0
500169
0.61
A
914254
D
Common Stock
2015-11-16
4
P
0
97269
1.43
A
1011523
D
Common Stock
2015-11-17
4
P
0
606677
1.93
A
1618200
D
Common Stock
2015-11-17
4
P
0
7000
2.43
A
1625200
D
The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 500,169 shares in multiple transactions at prices ranging from $0.3 to $.79, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
The securities reported herein are owned directly by Martin Shkreli, who is a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly, Mr. Shkreli does not have a pecuniary interest in the shares owned by the other members of the group.
The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 606,677 shares in multiple transactions at prices ranging from $1.38 to $2.37, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 7,000 shares in multiple transactions at prices ranging from $2.38 to $2.45, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
s/ Martin Shkreli
2015-11-18